the coexistence of HBsAg and anti-HBs has been reported in some chronic hepatitis B patients; however, the long-term outcomes of this serological profile have not been elucidated. We aimed to evaluate the long-term outcomes of HBsAg/anti-HBs double-positive chronic hepatitis B patients. chronic hepatitis B patients who underwent baseline abdominal ultrasonography and follow-up (HBsAg/anti-HBs assessment and abdominal ultrasonography) at our healthcare center were included. the "coexistence group" included patients positive for both HBsAg and anti-HBs and the "control group" included patients positive for only HBsAg during follow-up. The outcomes were hepatocellular carcinoma (HCC) incidence, HBsAg seroclearance and overall mortality. Kaplan-Meier and Cox proportional hazard regression analyses were performed. Of the 2,341 eligible patients, 166 (7.1%) were in the coexistence group. The total follow-up duration was 5.4 years. The coexistence group had a 3.08-fold higher risk of HCC than the control group [hazard ratio (HR) 3.08, 95% confidence interval(CI) 1.26-7.55, P = 0.014] in multivariate analysis. The coexistence group had more HBsAg seroclearance than the control group (HR 1.43, 95% CI 1.01-2.03, P = 0.046). However, overall mortality did not significantly differ between the 2 groups. The coexistence group is heterogeneous and includes subjects with unfavorable outcomes (incidence of HCC) and favorable outcomes (more HBsAg seroclearance).
Definition of HCC occurrence, cirrhosis and significant fibrosis. HCC was diagnosed according to
the guidelines of the American Association for the Study of Liver Disease 10 . The presence of cirrhosis was reviewed according to imaging findings of cirrhotic hepatic change and/or clinical criteria indicating portal hypertension, such as the presence of ascites, esophageal or gastric varix, or splenomegaly with thrombocytopenia.
Hepatic fibrosis was defined using a noninvasive prediction model Fibrosis-4 (FIB-4) index. The equation for FIB-4 index is as follows;
FIB-4 = age (years) x AST (U/L)/(platelets (10 9 /L) x [ALT (U/L)] 1/2 ) Subjects with FIB-4 > 1.45 were regarded as those who have high probability of advanced fibrosis 11,12 . Definition of groups and outcome measures. The coexistence of HBsAg and anti-HBs was defined by the simultaneous positivity for both HBsAg and anti-HBs. The "coexistence group" included chronic hepatitis B patients who were positive for both HBsAg and anti-HBs during follow-up. The transient or intermittent coexistence of HBsAg and anti-HBs during follow-up was also included in the "coexistence group". The dynamic change of HBsAg and anti-HBs of the patients in coexistence group is presented in Supplementary Fig. 1 . The "control group" include patients who never experienced coexistence of HBsAg and anti-HBs (HBsAg single-positive) during follow-up. The primary outcome was HCC incidence. Secondary outcomes were HBsAg seroclearance and all-cause mortality. HBsAg seroclearance was defined as the loss of serum HBsAg, not related to liver transplantation. The follow-up duration for HCC occurrence was calculated from the time of initial visit to the time of last evaluation of the image or the diagnosis of HCC. The follow-up duration for HBsAg seroclearance was calculated from the time of initial evaluation of HBsAg to the time of last HBsAg evaluation or HBsAg seroclearance. Predictors for outcomes were evaluated. All-cause mortality was evaluated in all subjects using the survival data provided by the National Micro Data Service System (Seoul, Korea).
Statistical analyses.
Continuous variables were expressed as the means ± standard deviations, and categorical variables were expressed as numbers and percentages. Between-group comparisons were performed using Student's t-tests or Mann-Whitney U tests for continuous variables and Chi-square tests or Fisher's exact tests for categorical variables.
Kaplan-Meier graphs were drawn, and log-rank tests were performed to compare the time to HCC incidence, HBsAg seroclearance and death due to any cause. Cox proportional hazard regression analysis was performed to identify the predictors of outcomes. As a sensitivity analysis, we also performed an analysis with propensity score (PS) matching to investigate if the coexistence with HBsAg/Ab affect the incidence of HCC. PS was generated by using a logistic regression analysis to compute the probabilities of HBsAg/Ab coexistence, as a function of 21 covariates which are listed in Supplementary Table 1 . Those in the coexistence group were matched (1:1) individually with those in control group based on PS. All the included variables were balanced between 2 groups. All statistical analyses were performed using Stata 14.2 (StataCorp, College Station, TX, USA) and SPSS 21 (SPSS Inc., Chicago, IL, USA), and P-values < 0.05 were considered statistically significant.
Results
Data at baseline and during follow-up. In total, 2,341 subjects were included in this study. Figure 1 shows a flowchart of study enrollment. The median age of the patients was 46.4 years, and 1,412 subjects were male (60.3%). The coexistence group accounted for 7.1% of the total population. Table 1 shows the baseline characteristics of the overall cohort, coexistence group and control group. There were no significant differences in age, sex, alanine aminotransferase (ALT) level, aspartate aminotransferase (AST) level, presence of cirrhosis, FIB-4 or history of antiviral medication. The follow-up durations were not different between the groups. Less subjects with qHBsAg > 250 IU/ml were included in the coexistence group.
Incidence of HCC. HCC was diagnosed in 37 patients (1.7%) in the control group and 6 patients (3.6%) in the coexistence group during the follow-up period. Based on the Kaplan-Meier analysis, a marginal association was observed between the coexistence of HBsAg and anti-HBs and HCC development (log-rank test, P = 0.071). In the multivariate Cox regression analysis, the coexistence of HBsAg and anti-HBs resulted in a 3.1-fold higher risk of HCC occurrence than the presence of HBsAg alone (hazard ratio (HR) 3.08, 95% confidence interval (CI) 1.26-7.55, P = 0.014). Male sex (HR 4.92, 95% CI 1.74-13.89, P = 0.003), presence of cirrhosis (HR 7.30, 95% CI 3.50-15.24, P < 0.001), significant fibrosis evaluated by FIB-4 (HR 4.52, 95% CI 2.10-9.74, P < 0.001), higher qHBsAg (HR 2.80, 95% CI 1.10-7.15, P = 0.032) were also significantly associated with HCC occurrence ( Table 2 and Fig. 2a ).
In the PS matched cohort, most variables were balanced between groups (Supplementary Table 1 ). The PS matched analysis also showed that coexistence of HBsAg and anti-HBs were independent risk factor for HCC development (HR 10.20, 95% CI 1.10-92.00, log-rank test = 0.015).
HBsAg seroclearance. HBsAg seroclearance was observed in 316 patients: 39/166 (23.5%) in the coexistence group, and 277/2175 (12.7%) in the control group. The cumulative probabilities of HBsAg seroclearance in the total population were 1.24% at 1 year, 5.75% at 3 years, and 10.78% at 5 years. The annual HBsAg seroclearance rate was 4.92% in the coexistence group and 2.56% in the control group.
Based on the Kaplan-Meier analysis, the coexistence group was associated with more HBsAg seroclearance (log-rank test < 0.001). The association between the coexistence of HBsAg and anti-HBs and HBsAg seroclearance (HR 1.43, 95% CI 1.01-2.03, P = 0.046) remained significant even after adjustment for covariates including age, sex, ALT level, presence of cirrhosis, significant fibrosis evaluated by FIB-4, history of antiviral medication, and qHBsAg level ( Table 3 and www.nature.com/scientificreports www.nature.com/scientificreports/ All-cause mortality. As shown in Table 4 and Fig. 2c , no significant difference was observed in overall mortality between the coexistence group and the control group. Older age (P = 0.010) and the presence of cirrhosis (P = 0.002) were predictive factors for overall mortality.
Discussion
This study evaluated the long-term clinical outcomes of the coexistence of HBsAg and anti-HBs. The proportion of HBsAg/anti-HBs double-positive chronic hepatitis B patients was 7.0% among in this study. The coexistence of HBsAg and anti-HBs was associated with a higher HCC risk and more HBsAg seroclearance than the presence of HBsAg alone. Nevertheless, overall mortality was not significantly different between the coexistence and control groups.
Our study showed a higher HBsAg/anti-HBs double positivity rate than that reported by previous studies (2.8% to 3.6%) [2] [3] [4] [5] . This might be due to the detection of double positivity during the follow-up duration. A previous longitudinal study similarly reported a HBsAg/anti-HBs double positivity rate of 7.1% 13 . Differences in the characteristics of study populations can also affect the prevalence of HBsAg and anti-HBs double positivity. For example, pre-S deletion, which is thought to be associated with the coexistence of HBsAg and anti-HBs, has been found more frequently in chronic hepatitis B patients with genotype C than in those with genotype B 14, 15 .
There are several plausible explanations for the coexistence of HBsAg and anti-HBs. First, selection of immune escape mutants might occur during chronic HBV infection despite the production of anti-HBs 1 . Mutations or deletions in the pre-S/S gene 16 , mutation in "a" determinant and in other regions of the "S" protein 17 or emergence of heterologous subtype-specific antibodies directed against HBsAg subtypes different from coexisting HBsAg 8, 18, 19 can explain this phenomenon 1 . Second, superinfection with a new HBV strain is another possible explanation 1, 20 . Infection with an HBV escape mutant has also been reported in the presence of anti-HBs even after vaccination 20, 21 . Third, HBV reactivation during occult HBV infection often associated with immunosuppressive conditions is another possible mechanism 22, 23 . Fourth, false positivity for anti-HBs antibody could explain the coexistence of HBsAg and anti-HBs, and this phenomenon can occur as a result of exposure to diverse naturally developing antigens or to other infections, such as Escherichia coli or Neiserria gonorrhoeae 24 28 . This patient had undetectable HBV DNA even after seroreversion to a HBsAg-positive state. By evaluated HBsAg seroclearance after nucleoside analog therapy, another study showed that HBsAg seroreversion occurred in some patients who experienced HBsAg seroclearance, most of which were transient with extremely low serum levels of HBsAg and HBV DNA 25 . According to these different mechanisms, the impact of HBsAg/ anti-HBs double positivity on outcomes could be different. However, the evaluation of viral mutations and genetic subtypes was not performed in this study. Thus, we could not determine the proportion of subjects affected by each of these possible underlying mechanisms or determine the main underlying mechanism for the coexistence of HBsAg and anti-HBs.
According to our results, the coexistence of HBsAg and anti-HBs was associated with HCC development. This result is consistent with the findings of a previous smaller study with a median of 4.3 years follow-up, which reported a 2-fold higher HCC occurrence rate in the coexistence group than HBsAg-only positive group 13 . Our study with 2,341 patients with an approximately 5 year follow-up showed similar results, reporting a 3.1-fold higher risk of HCC in the coexistence group than in the control group independent of other risk factors for HCC. As deletion of pre-S1 regions, one of possible mechanism for the HBsAg and anti-HBs double positive, has been suggested as a risk factor in progressive liver disease, including hepatocarcinogenesis 15, 29, 30 , this might explain the increase in HCC occurrence in the coexistence group. Further study evaluating the mutational status of pre-S1 in the coexistence and control groups might help to evaluate whether this phenomenon can explain the increased HCC incidence in the coexistence group.
Intriguingly, the coexistence of HBsAg and anti-HBs was also associated with increased HBsAg seroclearance, which is associated with good prognosis 25, 31, 32 . One plausible explanation for more HBsAg seroclearance is that patients who had anti-HBs after seroconversion and then experienced transient low-level HBsAg seroreversion were included in the coexistence group as presented above. As these patients usually have very low levels of HBsAg and tend to experience repeated seroclearance of HBsAg 25, 27 , this might explain better HBsAg seroclearance in the coexistence group than in the control group. Another plausible explanation is that seroclearance of HBsAg is not indicative viral clearance but rather of a point mutation in the S gene that results in the failure to www.nature.com/scientificreports www.nature.com/scientificreports/ detect HBsAg 33, 34 . In this study, only 10% of subjects (4 out of 39 patients) with HBsAg seroclearance in the coexistence group were subjected to HBV DNA level analysis at the time of seroclearance, and these 4 patients showed no or minimal level of HBV DNA (less than 20 IU/mL), suggesting true HBsAg seroclearance with viral clearance rather than detection failure.
The coexistence of HBsAg and anti-HBs was associated with a risk of HCC occurrence, which represents poor outcome. However, the coexistence of HBsAg and anti-HBs was also associated with HBsAg seroclearance, which represents a favorable outcome. Additionally, these events were mutually exclusive. In other words, in the coexistence group, 6 patients developed HCC, and 39 patients experienced HBsAg seroclearance during follow-up. However, no patient experienced both HBsAg seroclearance and HCC occurrence. This result suggests that the coexistence group is heterogeneous. More detailed serological analyses, including viral mutations, might help identify differences in these populations.
This study has several strengths. First, this study is the first to evaluate the long-term outcomes of HBsAg/ anti-HBs double-positive patients from several aspects, including HCC occurrence, HBsAg seroclearance, and overall mortality. Second, HBsAg was evaluated nearly annually in most patients with a mean of 4.4 times per patient over a 5-year follow-up period. As the level of HBsAg and anti-HBs is variable, the change in HBsAg and anti-HBs levels could be evaluated with this regular repeated follow-up.
This study has several limitations. First, although this study described longitudinal outcomes of patients positive for both HBsAg and anti-HBs, the underlying mechanism was not determined in this study, as mentioned above. Further studies, such as the evaluation of pre-S1 mutations, are warranted to evaluate the mechanism underlying higher HCC incidence or more HBsAg seroclearance in the coexistence group than in the control group. Second, a sufficient serological profile reflecting HBV infection status, such as HBeAg, anti-HBe and HBV DNA, was not evaluated in all subjects because of the nature of our health screening policy. Third, only Korean patients of a single ethnic origin, more than 99% of whom were infected by genotype C HBV, were included in this study 35 . To generalize these findings, validation in other ethnic groups with variable genotypes might be necessary.
In conclusion, this study shows the long-term outcomes of patients positive for both HBsAg and anti-HBs. The coexistence of HBsAg and anti-HBs was associated with higher HCC incidence rates and more HBsAg seroclearance than the presence of HBsAg alone. Nevertheless, overall mortality was not significantly different between the coexistence group and the control group. It suggests that the coexistence group could not be defined as one homogenous group, but consists of groups with favorable outcomes and groups with unfavorable outcomes.
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